Faculty

Institution

Unit

Venue

Robert C. Bast

Harry Carothers Wiess Distinguished University Chair for Cancer Research Harry Carothers Wiess Chair for Cancer Research

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Experimental Therapeutics

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

Department Of Thoracic-Head And Neck Medical Oncology

Division Of Cancer Medicine

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Robert C. Bast is the Harry Carothers Wiess Distinguished University Chair for Cancer Research at The University of Texas MD Anderson Cancer Center. His research focuses on ovarian cancer biology, tumor biomarkers, and therapeutic resistance mechanisms. Recent work includes developing novel serum glycoprotein biomarkers for earlier ovarian cancer recurrence detection, investigating DIRAS3-mediated suppression of MAPK/PI3K pathways across KRAS mutations, and exploring SIK2/3 inhibition to induce ER stress and autophagy blockade. He has demonstrated that GRN-300 restores PARP inhibitor sensitivity via the HDAC-MEF2A-RAD51 pathway in BRCA2-revertant tumors. His translational efforts bridge cell signaling, gynecologic oncology, and pharmacology, supported by awards including a grant for GRN-300 in triple-negative breast cancer.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Robert C. Bast

The University of Texas MD Anderson Cancer Center

Harry Carothers Wiess Distinguished University Chair for Cancer Research Harry Carothers Wiess Chair for Cancer Research

You can click a keyword to filter the displayed items

ovarian cancer gynecologic oncology oncology gynecology cancer biology tumor biology cancer research cancer cells cell biology gynecologic cancers oncogenes pathology pharmacology cancer treatment medicinal research molecular cancer cancer care breast cancer cancer discovery cancer genetics cancer detection cell signaling tumor suppressors gene expression anti-cancer agents cancer management cancer imaging cancer growth obstetrics and gynaecology tumor targeting autophagy molecular diagnostics cancer genomics endocrine-related cancers breast oncology cell death molecular cell biology epithelial ovarian cancer ovarian cancer cells cell regulation signaling pathways surgical oncology cellular therapy cancer screening obstetrics tumoral pathology cancer risk apoptosis malignant disease molecular pathology prognostic biomarkers pharmacotherapy oncogenic agent early detection ca 125 gynecological surgery receptor tyrosine kinases monoclonal antibody cancer prevention antibody engineering cytokines endocrine oncology clinical evidence breast cancer cells tumor markers tumor heterogeneity epithelial ovarian carcinoma ovarian carcinoma bone marrow monoclonal antibodies human ovarian carcinoma high-dose chemotherapy human bone marrow human ovarian cancer serum levels pelvic mass metastasis cell research epigenetics reproductive immunology reproductive endocrinology endocrinology developmental cell cell division tumor microenvironment jama oncology cellular differentiation leukemia reproductive medicine therapeutic targets cancer immunotherapy developmental biology cancer letter immunotherapy immunology carcinogenesis radiation oncology systems biology brain tumor research reproductive science signal transduction molecular medicine experimental medicine embryology

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 323: Dual Inhibition of Sik2/3 Induces Er Stress and Er-Phagy, Enhancing the Cytotoxicity of Autophagy Blockade in Ovarian Cancer.. Cancer Research (2026)

pharmacologycancer biologyabstract 323cancer cellsautophagy blockadeautophagycell autophagyovarian cancercell signalingimmunologycell biologycell deaththerapeutic targetsdual inhibition

Abstract 357: Diras3 Mimetic Peptide Achieves Dual Mapk and Pi3K Pathway Suppression Across Kras Hotspot Mutations.. Cancer Research (2026)

diras3 mimetic peptidedual mapkmolecular cell biologysignal transductionkras hotspot mutationsproteome researchmolecular biologycell signalingprotein phosphorylationsignaling pathwayscell biologymolecular and cellular biologyprotein sciencecellular biochemistrymutagenesis (molecular biology technique)

Abstract 6522: Novel Serum Biomarkers That Detect Ovarian Cancer Recurrence Earlier Than Ca125. Cancer Research (2026)

biomarker targetabstract 6522biomarker discoverybiomarkersovarian cancerprognostic biomarkersnovel serum biomarkerscell biologymolecular diagnosticsgynecologic oncologygynecologyovarian cancer recurrence

Abstract 7130: Grn-300 Restores Parp Inhibitor Sensitivity Through Inhibition of the Hdac-Mef2A-Rad51 Pathway in Brca2-Revertant Ovarian Cancer. Cancer Research (2026)

pharmacologycancer biologymolecular cancertumor suppressorscancer cellsoncogeneshdac-mef2a-rad51 pathwaybrca2-revertant ovarian cancercancer discoveryovarian cancerabstract 7130anti-cancer agentscancer geneticscell biologygynecologic cancersgynecologic oncologygynecologytherapeutic targets

Abstract 1689: Targeting Parp to Enhance Sensitivity to Mek Inhibitors in Low-Grade Serous Ovarian Cancer. Cancer Research (2025)

pharmacologycancer biologycancer treatmentcancer cellsoncologyovarian cancerabstract 1689mek inhibitorsanti-cancer agentstumor biologycell biologygynecologic cancersgynecologic oncologygynecologytherapeutic targets

Diras3-Derived Cyclic Peptides Disrupt Kras-Raf Interaction and Kras Nanoclustering, Suppressing Kras-Driven Pancreatic and Ovarian Tumors. iScience (2025)

cancer biologynanomedicinetumor suppressorstumor targetingcancer cellsoncogenespeptide sciencediras3-derived cyclic peptidescancer discoverybiochemistrydrug targetingtumor biologykras-raf interactioncell biologytherapeutic targetskras nanoclustering

Diras3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin β1/Fak/Akt Signaling Pathway. Cells (2025)

cancer biologymolecular cell biologycancer cellsoncogenesovarian cancermolecular biologycell regulationcell signalingtumor biologysignaling pathwayscell biologytherapeutic targetscancer growth

Glycoknow Ovarian: A Glycoprotein-Based, Serum Diagnostic to Distinguish Ovarian Cancers From Benign Pelvic Masses. medRxiv (2025)

pathologygynecological surgerytumoral pathologyglycoknow ovariansurgical pathologyovarian cancersoncologyovarian cancerserum diagnosticgynecologic cancersgynecologic oncologygynecology

Quantitative Proteomics Identifies Conserved Proteins and Altered Regulation of Mucin-16 in Low Grade Serous Ovarian Cancers. Clinical Proteomics (2025)

cancer biologyproteomic technologiescancer cellsproteomicsclinical proteomicsproteome researchtranslational proteomicsovarian cancerquantitative proteomics identifiestumor biologyaltered regulationcell biologygynecologic cancersgynecologic oncologygynecology

Abstract 1215: Diras3 Inhibits Oncogenic Ras Signaling and Ras-Dependent Cell Growth Driven by Prevalent Kras Hot Spot Mutations. Cancer Research (2024)

Gamze BildikJunchen LiuWeiqun MaoHailing YangJohn F. HancockRobert C. BastZhen Lu

cancer biologyras-dependent cell growthoncogenic rascancer researchmolecular biology

1
2
3
4
5
71
10 / page

Robert C. Bast

Harry Carothers Wiess Distinguished University Chair for Cancer Research Harry Carothers Wiess Chair for Cancer Research

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Experimental Therapeutics

Department Of Gynecologic Oncology And Reproductive Medicine

Department Of Gynecologic Research

Department Of Thoracic-Head And Neck Medical Oncology

Division Of Cancer Medicine

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Robert C. Bast

The University of Texas MD Anderson Cancer Center

Harry Carothers Wiess Distinguished University Chair for Cancer Research Harry Carothers Wiess Chair for Cancer Research

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 323: Dual Inhibition of Sik2/3 Induces Er Stress and Er-Phagy, Enhancing the Cytotoxicity of Autophagy Blockade in Ovarian Cancer.. Cancer Research (2026)

pharmacologycancer biologyabstract 323cancer cellsautophagy blockadeautophagycell autophagyovarian cancercell signalingimmunologycell biologycell deaththerapeutic targetsdual inhibition

Abstract 357: Diras3 Mimetic Peptide Achieves Dual Mapk and Pi3K Pathway Suppression Across Kras Hotspot Mutations.. Cancer Research (2026)

Abstract 6522: Novel Serum Biomarkers That Detect Ovarian Cancer Recurrence Earlier Than Ca125. Cancer Research (2026)

Abstract 7130: Grn-300 Restores Parp Inhibitor Sensitivity Through Inhibition of the Hdac-Mef2A-Rad51 Pathway in Brca2-Revertant Ovarian Cancer. Cancer Research (2026)

Abstract 1689: Targeting Parp to Enhance Sensitivity to Mek Inhibitors in Low-Grade Serous Ovarian Cancer. Cancer Research (2025)

Diras3-Derived Cyclic Peptides Disrupt Kras-Raf Interaction and Kras Nanoclustering, Suppressing Kras-Driven Pancreatic and Ovarian Tumors. iScience (2025)

Diras3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin β1/Fak/Akt Signaling Pathway. Cells (2025)

cancer biologymolecular cell biologycancer cellsoncogenesovarian cancermolecular biologycell regulationcell signalingtumor biologysignaling pathwayscell biologytherapeutic targetscancer growth

Glycoknow Ovarian: A Glycoprotein-Based, Serum Diagnostic to Distinguish Ovarian Cancers From Benign Pelvic Masses. medRxiv (2025)

pathologygynecological surgerytumoral pathologyglycoknow ovariansurgical pathologyovarian cancersoncologyovarian cancerserum diagnosticgynecologic cancersgynecologic oncologygynecology

Quantitative Proteomics Identifies Conserved Proteins and Altered Regulation of Mucin-16 in Low Grade Serous Ovarian Cancers. Clinical Proteomics (2025)

Abstract 1215: Diras3 Inhibits Oncogenic Ras Signaling and Ras-Dependent Cell Growth Driven by Prevalent Kras Hot Spot Mutations. Cancer Research (2024)

Gamze BildikJunchen LiuWeiqun MaoHailing YangJohn F. HancockRobert C. BastZhen Lu

cancer biologyras-dependent cell growthoncogenic rascancer researchmolecular biology

1
2
3
4
5
71
10 / page